Business
Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
New York, May 20, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on Imugene Ltd. (ASX: IMU) resuming coverage. The research summary below is from a report commissioned by Imugene Ltd. and produced by Diamond Equity Research. The in-depth 24-page update note includes detailed information on the Imugene’s business model, industry, financial results, and risks. The full research report is av
About this update from Imugene Ltd
[{"type":"text","content":"New York, May 20, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on Imugene Ltd. (ASX: IMU) resuming coverage. The research summary below is from a report commissioned by Imugene Ltd. and produced by Diamond Equity Research. The in-depth 24-page update note includes detailed information on the Imugene’s business model, industry, financial results, and risks.","length":469,"tagName":"p"},{"type":"text","content":"The full research report is available below.","length":44,"tagName":"p"},{"type":"text","content":"Imugene Ltd. Resumption of Coverage","length":35,"tagName":"p"},{"type":"text","content":"Highlights from the report include:","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Azer-cel Drives the Central Investment Case through a Differentiated off-the-shelf CAR-T Approach - Imugene’s investment case is increasingly anchored around azer-cel, an allogeneic CD19 CAR-T therapy that addresses several structural limitations of autologous CAR-T, including long manufacturing timelines, patient-specific production complexity, and constrained real-world access. By enabling pre-manufactured, donor-derived treatment with a materially shorter vein-to-vein time (3-5 days vs 2-4 weeks for autologous), azer-cel is positioned with certain catalysts to improve treatment accessibility in aggressive B-cell malignancies where speed of deployment is clinically important. Beyond speed, the allogeneic approach enables batch-based manufacturing, improving scalability and product consistency while leveraging healthy donor-derived cells. Additionally, inventory-based distribution allows immediate treatment availability, eliminating logistical bottlenecks associated with autologous therapies. Economically, autologous CAR-T therapies are priced at $400,000-$500,000 per patient, while allogeneic approaches are structurally more cost-efficient. Collectively, these factors position azer-cel as potentially a more accessible and scalable alternative within the CAR-T paradigm.","length":1291,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical Data Provide Early Validation in High-Risk, Heavily Pre-Treated Populations - Azer-cel’s current clinical evidence base is now best framed around Imugene’s ongoing Pha...